4-N-[2-(4-phenoxyphenyl)ethyl]quinazoline-4,6-diamine

QNZ (EVP4593, CAY-10470) is a highly potent and selective small-molecule inhibitor of the nuclear factor κB (NF-κB) signaling pathway and tumor necrosis factor alpha (TNF-α) production. Its IC50 values for NF-κB and TNF-α inhibition are 11 nM and 7 nM in human Jurkat T cells, respectively[1][2][5]. QNZ is a quinazoline derivative, originally described as a modulator of NF-κB signal transduction in 2003[6]. The drug indirectly inhibits the NF-κB pathway by blocking store-operated calcium entry (SOCE) through calcium channels, potentially involving TRPC1 as a subunit[3][6]. QNZ exhibits neuroprotective effects in models of Huntington’s disease, reduces dendritic spine loss, and rescues mushroom spines in Alzheimer’s disease-related neurons[3][6]. QNZ also shows anti-inflammatory activity, suppressing Th1 and Th17 cell differentiation and neuroinflammation in animal models of multiple sclerosis[4]. Additionally, QNZ is identified as a selective inhibitor of mitochondrial complex I[3]. Research suggests potential therapeutic applications in neurodegenerative, inflammatory, and autoimmune diseases, but QNZ remains experimental and is not approved for clinical use in humans.

Other names

CAY 10470CAY10470CAY-104706-Amino-4-(4-phenoxyphenylethylamino)quinazolineN4-(4-phenoxyphenethyl)quinazoline-4,6-diamine545380-34-5NF-kB activation inhibitor